Apparent and true resistant hypertension: Definition, prevalence and outcomes

Journal of Human Hypertension

Volumn 28, Issue 8, 2014, Pages 463-468

  Judd, E ^a   Calhoun, D A ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

blood pressure; control; epidemiology; hypertension; prevalence; resistant

Indexed keywords

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); EUROPE; HUMAN; KIDNEY DENERVATION; MEDICATION COMPLIANCE; NORTH AMERICA; OUTCOME ASSESSMENT; PREVALENCE; RESISTANT HYPERTENSION; RETROSPECTIVE STUDY; REVIEW; COMPLICATION; DRUG RESISTANCE; HYPERTENSION;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPERTENSION; PREVALENCE;

EID: 84904051999     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2013.140     Document Type: Review

References (33)

1. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004; 22: 11-19.
2. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M et al. Hypertension and blood pressure levels in 6 European countries, Canada, and the US. JAMA 2003; 289: 2363-2369.
3. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA 2010; 303: 2043-2050.
4. Falaschetti E, Chaudhury M, Mindell J, Poulter N. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 2009; 53: 480-486.
5. Verdecchia P, Gentile G, Angeli F, Mazzotta G, Mancia G, Reboldi G. Influence of blood pressure reduction on composite cardiovascular endpoints in clinical trials. J Hypertens 2010; 28: 1356-1365.
6. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967-1975.
7. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
8. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372.
9. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.
10. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-1123.
11. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578-581.
12. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-17.
13. Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Göke B et al. HYDRA Study Group. High prevalence and poor control of hypertension in primary care: crosssectional study. J Hypertens 2004; 22: 479-486.
14. Giannattasio C, Cairo M, Cesana F, Alloni M, Sormani P, Colombo G et al. Blood pressure control in Italian essential hypertensives treated by general practitioners. Am J Hypertens 2012; 25: 1182-1187.
15. Sarafidis PA. Epidemiology of resistant hypertension. J Clin Hypertens (Greenwich) 2011; 13: 523-528.
16. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension - its identification and epidemiology. Nat Rev Nephrol 2013; 9: 51-58.
17. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD et al. American Heart Association Scientific Statement. Resistant hypertension: diagnosis, evaluation, and treatment. Hypertension 2008; 51: 1403-1419.
18. Calhoun DA. Apparent and true resistant hypertension: why not the same? J Am Soc Hypertens 2013; 7(6): 509-511.
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
20. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-2816.
21. McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Ther 2009; 31: 1116-1123.
22. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Amario P et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57: 898-902.
23. Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57: 1076-1080.
24. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988-2008. Circulation 2011; 124: 1046-1058.
25. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
26. Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc 2013; 88: 1099-1107.
27. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012; 125: 1635-1642.
28. Pierdomenico SD, Lapenna D, Bucci A, Di Tommaso R, Di Mascio R, Manente BM et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension. Am J Hypertens 2005; 18: 1422-1428.
29. Salles GF, Cardoso CR, Muxfeldt ES. Prognostic influence of office and ambulatory blood pressures in resistant hypertension. Arch Intern Med 2008; 168: 2340-2346.
30. Redon J, Campos C, Narciso ML, Rodicio JL, Pascual JM, Ruilope LM. Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. Hypertension 1998; 31: 712-718.
31. Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013; 31: 766-774.
32. Acelajado MC, Pisoni R, Dudenbostel T, Dell'Italia LJ, Cartmill F, Zhang B et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14: 7-12.
33. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH et al. The ALLHAT Collaborative Research Group. Success and predictors of blood pressure control in diverse North American settings: the Antihypertensive and Lipid- Lowering and Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens 2002; 4: 393-404.